BILLEV PHARMA ApS: Financial statements 2014
CVR: 81814813
Source: annual report 2014, Danish Business Authority
01/05/2013 – 30/04/2014
BILLEV PHARMA ApS (CVR 81814813) has filed annual accounts for 2014. In 2014, the company reported a gross profit of DKK 9,724,193 and a net result of DKK 516,674 compared with DKK 727,552 the year before. That is an increase of 3.3% compared with the year before. Equity in the 2014 report amounted to DKK 1,457,903. The solvency ratio was 27.8%.
- Gross Profit
- DKK 9,724,193
- Profit/Loss
- DKK 516,674
- Equity
- DKK 1,457,903
- Total Assets
- DKK 5,251,626
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2014 | - | 9.7 mio. | 517 t. | 1.5 mio. | - |
| 2013 | - | 9.4 mio. | 728 t. | 2.4 mio. | - |
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
As of October 10, 2014, EY Godkendt Revisionspartnerselskab has been appointed auditor of BILLEV PHARMA ApS.
As of October 10, 2014, JUT NR. 2180 A/S has stepped down as auditor of BILLEV PHARMA ApS.
About BILLEV PHARMA ApS
BILLEV PHARMA ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 1977. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Ulrikke Lynge Jensen and Anja Wencke van Arkens. The company is owned by VAN ARKENS HOLDING ApS and UL JENSEN HOLDING ApS. The company has 15 employees (2018). In 2026, the company reported a gross profit of DKK 38,801,270 and a net result of DKK 10,205,639 compared with DKK 6,143,854 the year before. Equity in the 2026 report amounted to DKK 10,525,639.